Pharmacokinetic study of iptacopan and its two acyl glucuronide metabolites in monkey plasma by liquid chromatography combined with electrospray ionization tandem mass spectrometry
Authors:
- 3 September 2024
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 38 (11) , e6002
Abstract
In this study, a simple and sensitive liquid chromatography tandem mass spectrometric method was developed and validated for the determination of iptacopan and two acyl glucuronidation metabolites in monkey plasma. The plasma sample was precipitated with acetonitrile and then separated on an Acquity UPLC BEH C18 column (2.1 × 100 mm, 1.7 μm) using 0.1% formic acid and 5 mM ammonium acetate in water and acetonitrile as the mobile phase. The mass spectrometry (MS) detection was performed in positive multiple reactions monitoring (MRM) mode with precursor‐to‐production transitions. The developed assay was validated over the range of 1–2000 ng/mL for three analytes with correlation coefficient ( r ) more than 0.99. The validation parameters including accuracy, precision, carryover effect, matrix effect, recovery, and stability were all within the acceptable limits. The validated method has been applied to investigate the pharmacokinetics of iptacopan and its two acyl glucuronidation metabolites in monkey plasma. After intravenous administration, iptacopan showed low clearance (2.75 mL/min/kg) in monkey plasma. After oral administration, the bioavailability was 55.43%. The exposure (AUC 0− t ) of direct acyl glucuronide (AG) of iptacopan accounts for 9.73% of the iptacopan plasma exposure. The AUC 0− t of AG of dealkylated metabolite of iptacopan was present at a lower level, accounting for 0.5% of the iptacopan plasma exposure.Keywords
This publication has 13 references indexed in Scilit:
- Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trialThe Lancet Haematology, 2021
- Pharmacokinetics and metabolism of LNP023 in rats by liquid chromatography combined with electrospray ionization–tandem mass spectrometryBiomedical Chromatography, 2020
- New Perspectives on Drug-Induced Liver Injury Risk Assessment of Acyl GlucuronidesChemical Research in Toxicology, 2020
- Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated DiseasesJournal of Medicinal Chemistry, 2020
- Bioanalytical challenges and strategies for accurately measuring acyl glucuronide metabolites in biological fluidsBiomedical Chromatography, 2019
- Small-molecule factor B inhibitor for the treatment of complement-mediated diseasesProceedings of the National Academy of Sciences, 2019
- Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal HemoglobinuriaSeminars in Hematology, 2018
- Acyl glucuronide metabolites: Implications for drug safety assessmentToxicology Letters, 2017
- Complement, a target for therapy in inflammatory and degenerative diseasesNature Reviews Drug Discovery, 2015
- Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl GlucuronideDrug Metabolism and Disposition, 2010